Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Explicyte has been selected by biotech company Cure51 to participate in the world's largest study.

Patient who overcame brain tumour to play key role in Cure51 ‘super-survivor’ cancer study.

French techbio company Cure51 has partnered with NVIDIA to accelerate research into a rare phenomenon: cancer patients who survive against the odds.

If we want to make true progress in the fight against cancer, we need to radically shift our focus.

Nicolas Wolikow, co-founder and president of Cure 51, was Laure Closier's guest on French Tech.

Katherine Webster will participate in a trial aimed at understanding the biological factors that enabled her to survive stage 4 glioblastoma.

We’re thrilled to announce that Cure51 is officially part of the NVIDIA DGX Cloud Innovation Lab and Inception Program!

Cure51 has announced the UK launch of the Rosalind study.